C1M | C5M | C6M | VICM | |
β (95% CI) | β (95% CI) | β (95% CI) | β (95% CI) | |
Unadjusted | 0.01 (0.00 to 0.03) | −0.00 (-0.12 to 0.11) | −0.00 (-0.03 to 0.02) | −0.00 (-0.03 to 0.02) |
Adjusted for age, gender and symptom duration | 0.02 (-0.00 to 0.04) | −0.02 (-0.15 to 0.10) | −0.00 (-0.03 to 0.03) | −0.00 (-0.03 to 0.03) |
Adjusted for age, gender, symptom duration and baseline mSASSS | 0.02 (-0.00 to 0.03) | −0.01 (-0.14 to 0.11) | −0.00 (-0.03 to 0.03) | 0.00 (-0.03 to 0.03) |
Adjusted for age, gender, symptom duration, mSASSS and CRP | 0.00 (-0.03 to 0.03) | −0.00 (-0.12 to 0.12) | −0.01 (-0.04 to 0.02) | −0.03 (-0.06 to 0.00) |
Adjusted for age, gender, symptom duration, mSASSS and ASDAS | 0.02 (-0.01 to 0.04) | −0.01 (-0.14 to 0.11) | −0.00 (-0.03 to 0.02) | −0.00 (-0.03 to 0.03) |
ASDAS, Ankylosing Spondylitis Disease Activity Index; C1M, C5M and C6M, MMP-mediated degradation of type I, V and VI collagen; respectively; CRP, C-reactive protein; mSASSS, modified Stoke Ankylosing Spondylitis Spine; MMP, matrix metalloproteinase; VICM, citrullinated and MMP-degraded vimentin.